To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

May 21, 2020___

Today's Rundown

Featured Story

Gilead's filgotinib phase 3 hits primary endpoint but details dampen hopes

A phase 2b/3 trial of Gilead Sciences' and Galapagos’ filgotinib in ulcerative colitis patients has met its primary endpoint. Yet, with the lower dose missing a key endpoint, investors responded negatively to the data, sending shares in Galapagos down 7% in early trading in Amsterdam.

Top Stories

CanSino adds mRNA to COVID-19 vaccine efforts with Precision NanoSystems deal

CanSino Biologics is already testing a recombinant conronavirus vaccine in China, but it’s jumping on the mRNA vaccine bandwagon through a licensing deal with Precision NanoSystems. The latter will design the vaccine, while CanSino will pick up preclinical and clinical development, regulatory activities and commercialization.

Day One debuts with $60M to change cancer care—starting with children

Day One Biopharmaceuticals is launching with a $60 million series A from Canaan, Access Biotechnology and Atlas Venture to develop new cancer treatments for children, but that could be used in adult patients, too. Its first program? A RAF inhibitor from Sunesis Pharma that was previously licensed by Takeda.

AstraZeneca scores $1.2B from U.S., signs up to deliver hundreds of millions of COVID-19 vaccines

Only days after Moderna reported positive early results for its potential COVID-19 vaccine, AstraZeneca has stolen the spotlight back. On Thursday, the U.K. drug giant scored a $1 billion contribution from the United States for development, production and delivery of its potential shot starting this fall. 

SR One fuels HotSpot's $65M B round to fund allosteric R&D

HotSpot Therapeutics has raised a $65 million series B to fund development of allosteric medicines. The financing, which was led by GlaxoSmithKline’s SR One, positions HotSpot to move treatments for autoimmune disease and rare metabolic conditions into the clinic.  

Nautilus emerges with $76M to become the 'Illumina of proteomics'

The vast majority of FDA-approved drugs target proteins, which makes sense because “they’re the machinery inside cells that make your body work,” says Sujal Patel, co-founder and CEO of Nautilus Biotechnology. What doesn’t make sense, he says, is we haven’t figured out a way to effectively measure proteins the same way we measure genes.

Kadmon’s graft-versus-host disease med on track for 2020 filing

Kadmon’s belumodsil curbed graft-versus-host disease in nearly three-quarters of patients in a pivotal study, teeing up an FDA filing in the fourth quarter. After six months of treatment, the drug improved symptoms of graft-versus-host disease (GVHD) in 73% of patients who took the drug once a day and 74% of patients who took it twice a day.

Harvard animal studies suggest COVID-19 protection can come from previous infection or DNA vaccine

Two animal studies out of Harvard showed DNA vaccines against COVID-19 generated similar levels of antibodies that can neutralize the virus as the actual infection does. That will likely fuel enthusiasm for efforts to rapidly develop vaccines against the disease, though the researchers warned there are still several unanswered questions.

GSK taps Mammoth Biosciences to develop a CRISPR-based, over-the-counter coronavirus test

GlaxoSmithKline’s consumer products division is teaming up with Jennifer Doudna’s CRISPR-focused outfit Mammoth Biosciences to develop a new COVID-19 diagnostic that would be fast, hand-held and fully disposable.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Resources

[Case Study] Establishing Parameters for Success

Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study.

[Fact Sheet] Forecasting to Optimize Clinical Trial Supply Management

Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study.

[eBook] Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

[Podcast] Developing residual HCPs ELISA assay for biopharmaceutical products

Listen to our brand-new Frontage Laboratories podcast where you’ll take home tips for developing residual host cell proteins ELISA assay for biopharmaceutical products using commercial kits.

[Virtual Event] Cardiac Safety London Online

Join us for a day of discovery as global experts in Cardiology, Pharmacology and Diabetes discuss state of the art methods in early phase clinical research.

[Whitepaper] The great data transition: Making the move from claims to EHR data

The immediacy of EHR data availability can be significantly impactful, particularly as the health care system works to address COVID-19. Download this whitepaper to learn more.

[Report] Decentralized Trials - Where Does the Industry Stand?

Patient-facing digital technologies are playing an important role in clinical trials for new drugs and medical devices, to the point where conducting virtual trials is becoming mainstream. But terms like remote trials, direct-to-patient trials, hybrid trials, decentralized trials, and more all add to the confusion of what makes a trial "virtual."

[Whitepaper] Why Your Business Needs An Effective Cloud Strategy To Survive Now

Businesses must maintain pre-pandemic levels of productivity with smaller IT budgets. Learn why an effective Cloud Strategy is imperative for success in these unprecedented times.

[Webinar] Optimizing your excipient screening for vaccine formulation

You are invited to join Rousselot Biomedical for an insightful webinar on excipients for vaccine formulation. Highly purified gelatins can help accelerate vaccine development.

[Whitepaper] Continuous Manufacturing vs Batch: Deciding on the Best Solution for your Oral Solid Dose Product

Continuous Manufacturing vs. Batch for Oral Solid Dose

[Whitepaper] Flexible Design for Novel Trials

Download this case study to read about how Cenduit navigated these challenges, and successfully supports the trial sponsor to execute the umbrella trial with agility.

[Whitepaper] Critical API Attributes and the Major Impact They Can Have on Drug Product Development

Download this whitepaper to learn more about the importance of an integrated approach to formulation.

[Case Study] More Powerful Analytics Capabilities

Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI.

[Case Study] Precision Analytics for Product Launch and Growth

Pharma launch teams spend significant resources on data and analytics with limited ROI. Read this case study to learn how a Life Sciences company identified two times more patients best suited for therapy, using Clarify’s deep and longitudinal patient and HCP insights. 

[Whitepaper] Is Wurster Processing the Right Choice for My Multiparticulate Modified Release Dosage Form?

Wurster processing is a versatile technique for developing and manufacturing multiparticulates for modified release dosage forms. Read this whitepaper to determine whether Wurster processing is the right option for your project.

[Webinar] Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

In this webinar, the featured speaker will explore the key advances and critical hurdles for translating these emerging molecular biology technologies into real-world applications and commercial processes.

[Whitepaper] Assessing the Financial Impact of Translational Pharmaceutics®

Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug. Download the whitepaper.

[Magazine] Perspective: the patient edition

Report: Think you’re patient-centric? Think again. Find out how patients really feel about patient-centricity. Learn what they would like to experience along with tools and tips for maximising patient engagement across the product life cycle¬ – from clinical trials to service design and creative campaigns.

[Whitepaper] New Lonza Whitepaper on Modulating lgG Effector Function

This whitepaper summarises approaches for modulating antibody effector functions and pharmacokinetics, and provides examples of antibodies in clinical studies.

[GUIDE] Managing Clinical Trial Patient & Site Engagement During COVID-19

Leverage strategic solutions to respond to immediate challenges to patient and site engagement from COVID-19, and learn to maximize the FDA guidance on the conduct of clinical trials during a pandemic.

Events